Skip to main content
Bristol-Myers to acquire Celgene in $74B deal
1/8/2019

Bristol-Myers Squibb plans to acquire Celgene for $74 billion in one of history's biggest mergers of pharmaceutical companies. Celgene and BMS have successful cancer drugs on the market in Opdivo and Revlimid.

Full Story: